Literature DB >> 3873905

In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.

S Alvarez, M Jones, S Holtsclaw-Berk, J Guarderas, S L Berk.   

Abstract

We tested 53 clinical isolates of Branhamella catarrhalis recovered from patients with respiratory symptoms to determine the susceptibility of the isolates to 25 antimicrobial agents, including the newer beta-lactam antibiotics. Of the 53 strains, 46 (86.7%) were beta-lactamase producers. All the strains were susceptible to the majority of the new penicillins and cephalosporins. The combinations of amoxacillin-clavulanic acid and ticarcillin-clavulanic acid were also very active against the beta-lactamase-producing strains.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3873905      PMCID: PMC180113          DOI: 10.1128/AAC.27.4.646

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  NEISSERIA CATARRHALIS BACTEREMIA WITH MENINGITIS.

Authors:  L E PFISTER; M V GALLAGHER; T G POTTERFIELD; D W BROWN
Journal:  JAMA       Date:  1965-08-02       Impact factor: 56.272

2.  Letter: Neisseria catarrhalis endocarditis.

Authors:  A A Pollock; R S Holzman
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

3.  Neisseria catarrhalis endocarditis.

Authors:  D Douer; Y Danziger; J Pinkhas
Journal:  Ann Intern Med       Date:  1977-01       Impact factor: 25.391

4.  Branhamella catarrhalis pneumonia.

Authors:  M West; S L Berk; J K Smith
Journal:  South Med J       Date:  1982-08       Impact factor: 0.954

5.  Branhamella (Neisseria) catarrhalis systemic disease in humans. Case reports and review of the literature.

Authors:  G V Doern; M J Miller; R E Winn
Journal:  Arch Intern Med       Date:  1981-11

6.  Branhamella (Neisseria) catarrhalis--a lower respiratory tract pathogen?

Authors:  M A Johnson; W L Drew; M Roberts
Journal:  J Clin Microbiol       Date:  1981-06       Impact factor: 5.948

7.  Bronchopulmonary infection due to Branhamella catarrhalis: 11 cases assessed by transtracheal puncture.

Authors:  G Ninane; J Joly; M Kraytman
Journal:  Br Med J       Date:  1978-02-04

8.  Antibiotic susceptibility of beta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis.

Authors:  G V Doern; K G Siebers; L M Hallick; S A Morse
Journal:  Antimicrob Agents Chemother       Date:  1980-01       Impact factor: 5.191

Review 9.  High isolation rate of Branhamella catarrhalis from the nasopharynx in adults with acute laryngitis.

Authors:  L Schalén; P Christensen; C Kamme; H Miörner; K I Pettersson; C Schalén
Journal:  Scand J Infect Dis       Date:  1980

10.  Branhamella (Neisseria) catarrhalis: criteria for laboratory identification.

Authors:  G V Doern; S A Morse
Journal:  J Clin Microbiol       Date:  1980-02       Impact factor: 5.948

View more
  27 in total

1.  Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis.

Authors:  A Verghese; D Roberson; J H Kalbfleisch; F Sarubbi
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Classification of beta-lactamases from Branhamella catarrhalis in relation to penicillinases produced by other bacterial species.

Authors:  R Labia; M Barthelemy; C B Le Bouguennec; A Buu Hoi-Dang Van
Journal:  Drugs       Date:  1986       Impact factor: 9.546

3.  Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production.

Authors:  I Luman; R W Wilson; R J Wallace; D R Nash
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  In vitro activity of LY163892 against pathogens isolated from pediatric patients.

Authors:  W M Wenman; P C Kibsey; C A Gratton; V E Knight
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-06       Impact factor: 3.267

Review 5.  Antimicrobial susceptibility testing of Haemophilus influenzae, Branhamella catarrhalis, and Neisseria gonorrhoeae.

Authors:  G V Doern; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 6.  Beta-lactamase inhibitors from laboratory to clinic.

Authors:  K Bush
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

7.  Tetracycline and erythromycin resistance among clinical isolates of Branhamella catarrhalis.

Authors:  B A Brown; R J Wallace; C W Flanagan; R W Wilson; J I Luman; S D Redditt
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata.

Authors:  R J Wallace; V A Steingrube; D R Nash; D G Hollis; C Flanagan; B A Brown; A Labidi; R E Weaver
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

9.  Effect of inoculum size on results of macrotube broth dilution susceptibility tests with Branhamella catarrhalis.

Authors:  G V Doern; T Tubert
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

Review 10.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.